Educational

"India's CDMO edge isn't cheap pills anymore—it's complex science with auditable supply chains."

India's Contract Drug Manufacturing: The 2026 Reality Check

India processes nearly 50% of the world's generic prescriptions. But if you're still thinking "cheast pills and compliance risks," you're three years behind.

The industry has quietly evolved. The weak players have been consolidated or shut down. The survivors? They're competing on scientific complexity—think high-potency APIs, ADCs, and continuous manufacturing.

What smart buyers are looking for right now:

1. Certifications over claims. USFDA, WHO-GMP, or PICS. If a partner doesn't have these locked in, move on. Regulatory delays are real, but the right certs filter out 80% of the risk.

2. Raw material traceability. The "China Plus One" shift is in full swing. Ask your potential CMO: Where do your critical inputs come from? The best Indian manufacturers have built deep, local supply chains. The rest are still gambling on single sources.

3. Technology fit, not just price. Don't take an oral solid expert for sterile injectables. Specialisation matters more than ever. And if they're investing in AI-driven manufacturing or green chemistry? That's a sign they're planning for the next decade, not just surviving the quarter.

India is no longer the "cheap" option. It's the smart option. But smart buyers audit beyond the price sheet.

#Pharma #ContractManufacturing #CDMO #India #SupplyChainResilience

Educational content, not investment advice. Markets carry risk; read the disclosures on any Reco before you act on it.